ReviewFaculty reviews2021
Recent advances in the understanding and management of liposarcoma.
Review in Faculty reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 44 citations in OpenAlex.
- Liposarcoma: State of the Art-A Scoping Review.Medical sciences (Basel, Switzerland) · 2026Article
- KNTC1 and PRC1 define an immunosuppressive microenvironment and poor prognosis in liposarcoma.European journal of medical research · 2026Article
- Burden and unmet needs of liposarcoma in the United States: Patient perspectives on the liposarcoma diagnostic journey.Rare tumors · 2026Article
- Myxoid liposarcoma: treatment outcomes, metastatic pattern and volumetric analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Clinicopathological Implications of Maspin, CD8, and PD-L1 Expression in Liposarcomas.Current issues in molecular biology · 2025Article
- Histomorphological and molecular characteristics of liposarcoma (Review).Oncology letters · 2025Review
- Impact of vacuum assisted wound therapy on wound complications in STS surgery- A 3-year retrospective single-centre analysis.Langenbeck's archives of surgery · 2025Article
- Giant Intra-Abdominal Tumor, Compatible with Liposarcoma: A Case Report and Literature Review.The American journal of case reports · 2025Review
- Myxoid Liposarcoma of the Thigh in Early Puerperium-Rare Case Report and Narrative Review.Diseases (Basel, Switzerland) · 2025Article
- Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma.Future oncology (London, England) · 2025Article
- Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario.Current oncology (Toronto, Ont.) · 2025Article
- A Rare Case of Atypical Pelvic Retroperitoneal Lipoma Mimicking Liposarcoma; A Case Report and Review of Literature.Clinical case reports · 2025Article
- An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.Journal of molecular histology · 2024Review
- Surgical resection due to poor outcome of the immunotherapy of a relapsed mediastinal liposarcoma: a case report.Future science OA · 2024Article
- Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities.Frontiers in oncology · 2024Review
- Distribution and Rate of Myxoid Liposarcoma Spine Metastases: Impact on Surveillance Imaging.Annals of surgical oncology · 2023Article
- Article
- Effectiveness of tumor‑treating fields to reduce the proliferation and migration of liposarcoma cell lines.Experimental and therapeutic medicine · 2023Article
- Article
- Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma.Cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liposarcomas are a common subfamily of soft tissue sarcoma with several subtypes recognized by the World Health Organization: atypical lipomatous tumors (ALT)/well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid liposarcoma (MLPS), pleomorphic liposarcoma (PLPS), and myxoid pleomorphic liposarcoma (MPLPS). Despite shared adipocytic features among liposarcomas, the clinical approach to each subtype differs based on histology, location, clinical behavior, and specific oncogenic drivers. In this review, we highlight subtype-specific molecular features with the potential to generate novel therapies. We discuss recent clinical trials investigating the use of preoperative radiation therapy for retroperitoneal liposarcoma, chemotherapy, small molecule inhibitors, and innovative immunotherapy approaches and describe how we incorporate these advancements into the management of liposarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.